

Table 14-3.03
ADAS Cog (11) - Change from Baseline to Week 8 - LOCF

	Placebo (N=79)	Xanomeline Low Dose (N=81)	Xanomeline High Dose (N=74)
Baseline			
n	79	81	74
Mean (SD)	24.1 (12.19)	24.4 (12.92)	21.3 (11.74)
Median (Range)	21.0 (5;61)	21.0 (5;57)	18.0 (3;57)
Week 8			
n	79	81	74
Mean (SD)	25.0 (13.10)	26.2 (12.98)	22.3 (12.41)
Median (Range)	22.0 (5;62)	25.0 (5;62)	19.0 (2;62)
Change from Baseline			
n	79	81	74
Mean (SD)	0.8 (4.81)	1.8 (4.14)	1.0 (3.62)
Median (Range)	1.0 (-12;16)	2.0 (-12;14)	1.0 (-8;13)
p-value(Dose Response) [1][2]			0.497
p-value(Xan - Placebo) [1][3]		0.099	0.751
Diff of LS Means (SE)		1.1 (0.65)	0.2 (0.67)
95% CI		(-0.2;2.4)	(-1.1;1.5)
p-value(Xan High - Xan Low) [1][3]			0.195
Diff of LS Means (SE)			-0.9 (0.66)
95% CI			(-2.2;0.4)

[1] Based on Analysis of covariance (ANCOVA) model with treatment and site group as factors and baseline value as a covariate.

[2] Test for a non-zero coefficient for treatment (dose) as a continuous variable.

[3] Pairwise comparison with treatment as a categorical variable: p-values without adjustment for multiple comparisons.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rtf_eff1.sas

21:05 Monday, June 26, 2006